Is PLX or PMCB more undervalued in 2026?

CirclFi compares Protalix BioTherapeutics, Inc. (PLX) and PharmaCyte Biotech, Inc. (PMCB) using 13 institutional-grade valuation models. PLX has a Quality of Company score of 7.6/10 while PMCB scores 5.1/10.

Which is a better buy — PLX or PMCB?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do PLX and PMCB valuations compare?

PLX at $2.10 and PMCB at $0.86 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

PLX vs PMCB Valuation Comparison 2026 — Intrinsic Value Analysis

PLX

Biotechnology

Protalix BioTherapeutics, Inc.

Quality

7.6

out of 10

Value Trap

SAFE

Price

$2.10

Last close

Models

12/13

Active

PMCB

Biotechnology

PharmaCyte Biotech, Inc.

Quality

5.1

out of 10

Value Trap

SAFE

Price

$0.86

Last close

Models

4/13

Active

Model-by-Model Comparison

Model	Type	PLX Fair Value	PLX Upside	PMCB Fair Value	PMCB Upside
Bayesian DCF	Intrinsic	$1.66	-20.9%	—	—
Earnings Power Value	Intrinsic	$3.20	+52.2%	—	—
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$4.32	+105.5%	$5.13	+498.5%
ML-RIV	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
Dynamic NAV	Asset-Based	$0.50	-76.1%	$2.46	+186.9%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%
RCMH-DCF	Intrinsic	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for PLX vs PMCB — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

PLX vs PMCB — Which Stock Is More Undervalued?

PLX scores higher with a 7.6/10 quality rating vs PMCB's 5.1/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Protalix BioTherapeutics, Inc. (PLX) and PharmaCyte Biotech, Inc. (PMCB) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

PLX currently trades at $2.10 with a QOC of 7.6/10, while PMCB trades at $0.86 with a QOC of 5.1/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).